Life After PTSD and Brain Scientific Form Collaboration to Tackle PTSD
Life After PTSD and Brain Scientific Form Collaboration to Tackle PTSD
Life After PTSD, the developers of a leading PTSD treatment protocol, is investigating the use of Brain Scientific's NeuroCapTM and NeuroEEGTM system in its PTSD protocol
領先的PTSD治療方案的開發商Life After PTSD正在調查Brain Science的NeuroCap的使用情況TM和神經腦電圖TM系統在其PTSD協議中
LAKEWOOD RANCH, Fla., Feb. 23, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Brain Scientific (OTCQB:BRSFD), a Florida-based applied science technology company, announces today that it is collaborating closely with Life After PTSD (), which has purchased Brain Scientific's complete solution, NeuroCap and NeuroEEG, to determine how it could be incorporated into Life After PTSD's groundbreaking Managing Emotional States Effectively© (MESE) protocol to treat PTSD.
佛羅裏達州萊克伍德牧場，2023年2月23日(Global Newswire)--來自InvestorWire--總部位於佛羅裏達州的應用科學技術公司Brain Science(場外交易代碼：BRSFD)今天宣佈，它正在與購買了Brain Science的完整解決方案NeuroCap和NeuroEEG的創傷後應激障礙生活()密切合作，以確定如何將其納入創傷後應激障礙的突破性情緒狀態管理©(MESE)協議以治療創傷後應激障礙。
"We believe Brain Scientific's easy-to-use, quick-to-setup, integrated EEG solution will be an important component in our PTSD protocol," said Edward Maerkl, LMHC, first responder, veteran and one of the co-creators of the MESE protocol. "Our protocol is currently used by 80 practitioners who have used it successfully on more than 1,500 patients. This partnership will help us expand the protocol to thousands of practitioners across the United States."
LMHC的First Responder、資深人士、Mese協議的共同創建者之一Edward Maerkl説：“我們相信Brain Science易於使用、快速設置、集成的EEG解決方案將是我們PTSD協議的重要組成部分。我們的方案目前有80名從業者使用，他們已經成功地在1500多名患者身上使用過。這一夥伴關係將幫助我們將該方案擴大到全美數千名從業者。“
Life After PTSD's MESE protocol is the result of a collaboration between a psychiatrist, counselor and first responder to create a protocol based on the latest developments in brain science and counseling that can be learned quickly and used confidently by mental health professionals and community helpers alike. This revolutionary protocol allows clients to revisit distressing and traumatic memories from a safe distance, guided by a trained clinician or paraprofessional, to allow an alternate experience in which the event is significantly less triggering, with an enhanced ability to move forward.
創傷後應激障礙後的生活Mese方案是精神病學家、諮詢師和急救人員合作的結果，該方案基於腦科學和諮詢的最新發展，可以迅速學習並自信地被精神健康專業人員和社區幫助者使用。這一革命性的協議允許客户在訓練有素的臨牀醫生或輔助專業人員的指導下，從安全的距離重温痛苦和創傷的記憶，從而允許另一種體驗，在這種體驗中，事件的觸發大大減少，前進的能力得到增強。
"It's important to us to create products that are not only groundbreaking but also making an important and positive difference in our world," said Hassan Kotob, CEO of Brain Scientific. "We're delighted that Life After PTSD has selected Brain Scientific's integrated system to help them expand their PTSD treatment protocol and help those impacted by PTSD live better lives."
Brain Science首席執行官哈桑·科託布(Hassan Kotob)表示：“對我們來説，重要的是創造出不僅具有開創性，而且能對我們的世界產生重要和積極影響的產品。”我們很高興創傷後應激障礙後的生活選擇了腦科學公司的集成系統來幫助他們擴大創傷後應激障礙的治療方案，並幫助那些受到創傷後應激障礙影響的人過上更好的生活。“
About Brain Scientific
關於腦科學
Brain Scientific Inc. (brainscientific.com) is an applied sciences technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of medical and OEM devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap™ and NeuroEEG™ are smart neurological diagnostic devices that simplify administration, shorten scan time and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of OEM devices. To learn more about Brain Scientific's corporate strategy, products or investor relations, please visit brainscientific.com.
Brain Science Inc.是一家應用科學技術公司，擁有多項專利和FDA認證的產品。Brain Science致力於開發下一代解決方案，以推動醫療和OEM設備的未來。Brain Science有兩個產品線，涵蓋神經學和精密運動。NeuroCap™和NeuroEEG™是智能神經診斷設備，可簡化管理、縮短掃描時間並降低成本。Piezo Motion產品線由超高效緊湊型精密電機組成，將驅動下一代OEM設備。欲瞭解有關Brain Science公司的公司戰略、產品或投資者關係的更多信息，請訪問：brainScience fi.com。
Forward-Looking Statements
前瞻性陳述
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and the failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.
本新聞稿中包含的任何不描述歷史事實的陳述都可能構成前瞻性陳述。前瞻性陳述可能包括但不限於以下陳述：(I)未來業務的管理計劃和目標，包括與腦電產品和服務以及壓電電機技術的設計、開發和商業化有關的計劃或目標；(Ii)收入(包括收入/虧損)、每股收益(包括收益/虧損)、資本支出、股息、資本結構或其他財務項目的預測；(Iii)公司未來的財務表現；(Iv)Piezo Motion與Brain Science的成功整合；以及(V)以上第(I)、(Ii)、(Iii)或(Iv)點所述任何陳述所依據的或與之有關的假設。此類前瞻性陳述不是為了預測或保證實際結果、業績、事件或情況，也可能無法實現，因為它們是基於公司目前的預測、計劃、目標、信念、預期、估計和假設，受許多風險、不確定性和其他影響的影響，其中許多是公司無法控制的。由於這些風險和不確定性，某些事件和情況的實際結果和時間可能與前瞻性陳述中描述的大不相同。可能影響或導致前瞻性陳述不準確或導致實際結果與預期或期望結果大不相同的因素可能包括但不限於, 該公司無法獲得更多融資；與開發產品和相關產品相關的時間和資源過長；現金流不足和由此導致的流動性不足；該公司無法擴大其業務；政府對醫療器械和醫療保健行業的監管力度較大；缺乏產品多元化；該公司原材料價格波動；以及未能實施該公司的業務計劃或戰略。在該公司提交給美國證券交易委員會的文件中，對其中一些因素以及其他一些因素進行了識別和更詳細的描述。該公司不承諾更新這些前瞻性陳述。
CONTACTS
觸點
LIFE AFTER PTSD
info@lifeafterptsd.org
創傷後應激障礙後的生活
郵箱：INFO@LifeAfterptsd.org
INVESTORS
ir@brainscientific.com
投資商
郵箱：ir@brainScience fic.com
MEDIA
pr@brainscientific.com
媒體
電子郵箱：pr@brainScience fic.com
Corporate Communications
企業通信
IBN (InvestorBrandNetwork)
Los Angeles, California
310.299.1717 Office
Editor@InvestorBrandNetwork.com
IBN(InvestorBrandNetwork)
加利福尼亞州洛杉磯
310.299.1717辦公室
郵箱：EDITOR@InvestorBrandNetwork.com
譯文內容由第三人軟體翻譯。